Authors

Manmeet Ahluwalia, Miami Cancer InstituteFollow

Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma

Publication Date

10-21-2023

Content Type

Article

PubMed ID:

37864646

Additional Authors:

Additional authors and institutional affiliations

Citation

Strowd, R., Ellingson, B., Raymond, C., Yao, J., Wen, P. Y., Ahluwalia, M., Piotrowski, A., Desai, A., Clarke, J. L., Lieberman, F. S., Desideri, S., Nabors, L. B., Ye, X., & Grossman, S. (2023). Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. Journal of neuro-oncology, 165(1), 101–112. https://doi.org/10.1007/s11060-023-04456-7